CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.

Neurol Neuroimmunol Neuroinflamm · 2016 · PMC4990260 · PMID 27583276

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significancep = 0.068so close (0.05 < p ≤ 0.1)

While this suggested slower progression in the CoQ10 group, the difference did not reach statistical significance ( p = 0.068; table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.